Заключение
Повреждение миокарда, воздействие нейрогуморальных и иммунных систем активируют систему TGF-P и ряд смежных механизмов. Это приводит к трансдифференцировке клеток в миофибробласты, которые продуцируют компоненты внеклеточного матрикса.
Список литературы
1. Theocharis A.D., Manou D., Karamanos N.K. The extracellular matrix as a multitasking player in disease. The FEBS journal. 2019. vol. 286. no. 15. P. 2830-2869.
2. Iozzo R.V., Gubbiotti M.A. Extracellular matrix: the driving force of mammalian diseases. Matrix Biology. 2018. vol. 71. P. 1-9.
3. Li L., Zhao Q., Kong W. Extracellular matrix remodeling and cardiac fibrosis. Matrix Biology. 2018. vol. 68. P. 490-506.
4. Frangogiannis N.G. Cardiac fibrosis: cell biological mechanisms, molecular pathways and therapeutic opportunities. Molecular aspects of medicine. 2019. vol. 65. P. 70-99.
5. Nakamura M., Sadoshima J. Mechanisms of physiological and pathological cardiac hypertrophy. Nature Reviews Cardiology. 2018. vol. 15. no. 7. P. 387-407.
6. de Castro Brвs L.E., Frangogiannis N.G. Extracellular matrix-derived peptides in tissue remodeling and fibrosis. Matrix Biology. 2020. vol. 91-92. P. 176-187.
7. Fan D., Kassiri Z. Biology of Tissue Inhibitor of Metalloproteinase 3 (TIMP3), and Its Therapeutic Implications in Cardiovascular Pathology. Frontiers in Physiology. 2020. vol. 11. P. 661.
8. Liu T., Song D., Dong J., Zhu P., Liu J., Liu W., Ma X., Zhao L., Ling, S. Current understanding of the pathophysiology of myocardial fibrosis and its quantitative assessment in heart failure. Frontiers in Physiology. 2017. vol. 8. P. 238.
9. Tian J., An X., Niu L. Myocardial fibrosis in congenital and pediatric heart disease. Experimental and therapeutic medicine. vol. 13. no. 5. P. 1660-1664.
10. Fan D., Takawale A., Lee J., Kassiri Z. Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis & tissue repair. 2012. vol. 5. no. 1. P. 1-13.
11. Wrana J.L. Signaling by the TGFP superfamily. Cold Spring Harbor perspectives in biology. 2013. vol. 5. no. 10. P. a011197.
12. Dzialo E., Tkacz K., Blyszczuk P. Crosstalk between TGF-P and WNT signalling pathways during cardiac fibrogenesis. Acta Biochimica Polonica. 2018. vol. 65. no. 3. P. 341-349.
13. Blyszczuk P., Mьller-Edenborn B., Valenta T., Osto E., Stellato M., Behnke S., Glatz K., Basler K., Lьscher T.F., Distler O., Eriksson U., Kania G. Transforming growth factor-P-dependent Wnt secretion controls myofibroblast formation and myocardial fibrosis progression in experimental autoimmune myocarditis. European heart journal. 2017. vol. 38. no. 18. P. 1413-1425.
14. Verheule S., Sato T., Everett T. 4th, Engle S.K., Otten D., Rubart-von der Lohe M., Nakajima H.O., Nakajima H., Field L.J., Olgin J.E. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-P1. Circulation research. 2004. vol. 94. no. 11. P. 1458-1465.
15. Zeisberg M., Kalluri R. Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis. American Journal of Physiology-Cell Physiology. 2013. vol. 304. no. 3. P. C216-C225.
16. Kapur N. K. Wilson S., Yunis A.A., Qiao X., Mackey E., Paruchuri V., Baker C., Aronovitz M.J., Karumanchi S.A., Letarte M., Kass D.A., Mendelsohn M.E., Karas R.H. Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure. Circulation. 2012. vol. 125. no. 22. P. 2728-2738.
17. Itoh N., Ohta H. Pathophysiological roles of FGF signaling in the heart. Frontiers in Physiology. 2013. vol. 4. P. 247.
18. Chen C., Li R., Ross R.S., Manso A.M. Integrins and integrin-related proteins in cardiac fibrosis. Journal of molecular and cellular cardiology. 2016. vol. 93. P. 162-174.
19. Solaro R.J., Tardiff J.C. (eds) Biophysics of the failing heart: physics and biology of heart muscle. Springer: New York, 2013. 259 p.
20. Balasubramanian S., Quinones L., Kasiganesan H., Zhang Y., Pleasant D.L., Sundararaj K.P., Zile M.R., Bradshaw A.D., Kuppuswamy D. P3 integrin in cardiac fibroblast is critical for extracellular matrix accumulation during pressure overload hypertrophy in mouse. PLoS One. 2012. vol. 7. no. 9. P. e45076.
21. Takawale A., Zhang P., Patel V.B., Wang X., Oudit G., Kassiri Z. Tissue inhibitor of matrix metalloproteinase-1 promotes myocardial fibrosis by mediating CD63-integrin P1 interaction. Hypertension. 2017. vol. 69. no. 6. P. 1092-1103.
22. Zhang J., Fan G., Zhao H., Wang Z., Li F., Zhang P., Zhang J., Wang X., Wang W. Targeted inhibition of focal adhesion kinase attenuates cardiac fibrosis and preserves heart function in adverse cardiac remodeling. Scientific reports. 2017. vol. 7. no. 1. P. 1-12.
23. Shimojo N., Hashizume R., Kanayama K., Hara M., Suzuki Y., Nishioka T., Hiroe M., Yoshida T., Imanaka-Yoshida, K. Tenascin-C may accelerate cardiac fibrosis by activating macrophages via the integrin aVp3/nuclear factor-KB/interleukin-6 axis. Hypertension. 2015. vol. 66. no. 4. P. 757-766.
24. Murray I.R., Gonzalez Z.N., Baily J., Dobie R., Wallace R.J., Mackinnon A.C., Smith J.R., Greenhalgh S.N., Thompson A.I., Conroy K.P., Griggs D.W. av integrins on mesenchymal cells regulate skeletal and cardiac muscle fibrosis. Nature communications. 2017. vol. 8. no. 1. P. 1-13.
25. Lunde I.G., Herum K.M., Carlson C.C., Christensen G. Syndecans in heart fibrosis. Cell and tissue research. 2016. vol. 365. no. 3. P. 539-552.
26. Beetz N., Rommel C., Schnick T., Neumann E., Lother A., Monroy-Ordonez E.B., Zeeb M., Preissl S., Gilsbach R., Melchior-Becker A., Rylski B., Stoll M., Schaefer L., Beyersdorf F., Stiller B., Hein L. Ablation of biglycan attenuates cardiac hypertrophy and fibrosis after left ventricular pressure overload. Journal of molecular and cellular cardiology. 2016. vol. 101. P. 145-155.
27. Schaefer L., Tredup C., Gubbiotti M.A., Iozzo R.V. Proteoglycan neofunctions: regulation of inflammation and autophagy in cancer biology. The FEBS journal. 2017. vol 284. no 1. P. 10-26.
28. Shindo K., Asakura M., Min K.D., Ito S., Fu H.Y., Yamazaki S., Takahashi A., Imazu M., Fukuda H., Nakajima Y., Asanuma H., Minamino T., Takashima S., Minamino N., Mochizuki N., Kitakaze M. Cartilage intermediate layer protein 1 suppresses TGF-P signaling in cardiac fibroblasts. International Journal of Gerontology. 2017. vol. 11. no. 2. P. 67-74.
29. van Nieuwenhoven F.A., Munts C., Op't Veld R.C., Gonzвlez A., Diez J., Heymans S., Schroen B., van Bilsen M. Cartilage intermediate layer protein 1 (CILP1): a novel mediator of cardiac extracellular matrix remodelling. Scientific reports. 2017. vol. 7. no. 1. P. 1-9.
30. Xiang M., Luo H., Wu J., Ren L., Ding X., Wu C., Chen J., Chen S., Zhang H., Yu L., Zou Y., Xu H., Ye P., Chen M., Xia J. ADAM23 in cardiomyocyte inhibits cardiac hypertrophy by targeting FAK-AKT signaling. Journal of the American Heart Association. 2018. vol. 7. no. 18. P. e008604.
31. Nakamura Y., Kita S., Tanaka Y., Fukuda S., Obata Y., Okita T., Kawachi Y., Tsugawa-Shimizu Y., Fujishima Y., Nishizawa H., Miyagawa S., Sawa Y., Sehara-Fujisawa A., Maeda N., Shimomura I. A disintegrin and metalloproteinase 12 prevents heart failure by regulating cardiac hypertrophy and fibrosis. American Journal of Physiology-Heart and Circulatory Physiology. 2020. vol. 318. no. 2. P. H238-H251.
32. Mann D.L. (ed.) Heart Failure: A Companion to Braunwald's Heart Disease E-book. Elsevier Health Sciences, 2010. 902 p.
33. Ocaranza M.P., Riquelme J.A., Garda L., Jalil J.E., Chiong M., Santos R.A.S., Lavandero S. Counter-regulatory renin-angiotensin system in cardiovascular disease. Nature Reviews Cardiology. 2020. vol. 17. no. 2. P. 116-129.
34. AlQudah M., Hale T.M., Czubryt M.P. Targeting the renin-angiotensin-aldosterone system in fibrosis. Matrix Biology. 2020. vol. 91. P. 92-108.
35. Zhao W.B., Lu Q., Nguyen M.N., Su Y., Ziemann M., Wang L.N., Kiriazis H., Puthalakath H., Sadoshima J., Hu H.Y., Du X.J. Stimulation of p-adrenoceptors up-regulates cardiac expression of galectin-3 and BIM through the Hippo signalling pathway. British journal of pharmacology. 2019. vol. 176. no. 14. P. 2465-2481.
36. Forte M., Madonna M., Schiavon S., Valenti V., Versaci F., Zoccai G.B., Frati G., Sciarretta S. Cardiovascular pleiotropic effects of natriuretic peptides. International journal of molecular sciences. 2019. vol. 20. no. 16. P. 3874.